Vytorin in the Treatment of Alopecia Areata

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Subjects, non pregnant/lactating and over 18years old, with 40% alopecia areata will take vytorin (statin/ezetimibe) for 24 or 52 weeks and be monitored for hair regrowth.

The investigators hypothesize that Vytorin medication may have an effect on the inflammatory process of alopecia areata. Inactivating the inflammatory process may help in permitting hair regrowth in those subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Treatments: Ezetimibe, Simvastatin Drug Combination

Criteria

Inclusion Criteria:

• 40-80% hair loss.

• Clinical diagnosis of alopecia areata

• 18-years or older

Exclusion Criteria:

1. You are less than 18 years old

2. You are pregnant or planning to be pregnant during the next 12 months.

3. You are nursing a child.

4. You have kidney, liver or muscle disease.

5. You have an allergy to Lidocaine, the study drug or its components.

6. You are presently participating in another clinical trial

7. You are currently using, or have used within the past 3 months, the following:

• Systemic corticosteroids. (prednisone, methylprednisolone, hydrocortisone etc.)

• Immunosuppressant agents.(cyclosporine, efalizumab etc.)

• Any medication that may have interaction with Vytorin (check with the study doctor for other medications you are taking).

8. You are currently using, or have used within the past 2 weeks, any topical medication for the treatment of alopecia areata

9. You have an ongoing hypothyroid problem that is not being treated. If this problem is being treated then you can participate.